Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)Antibody-mediated Rejection; Microvascular InflammationEnrolling by invitationPhase 32026-10-09NCT07444489

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Biogen56

14 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
California Pacific Medical Center (Sutter Health)San FranciscoUnited States1
Cedars-Sinai Medical CenterLos AngelesUnited States392
Cleveland ClinicClevelandUnited States558
Cooperman Barnabas Medical CenterWest OrangeUnited States3
Keck Medical Center of USCLos AngelesUnited States21
Mayo ClinicRochesterUnited States664
Medical College of WisconsinMilwaukeeUnited States483
Penn Medicine - Hospital of the University of PennsylvaniaPhiladelphiaUnited States3
The Ohio State UniversityColumbusUnited States191
UCLA College of MedicineLos AngelesUnited States1
University of Nebraska Medical Center (UNMC) - Nebraska Medicine - Nebraska Medical CenterOmahaUnited States1
University of Washington Medical CenterSeattleUnited States104
Virginia Commonwealth UniversityRichmondUnited States156
Washington University School of MedicineSt LouisUnited States895